These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
554 related articles for article (PubMed ID: 28209290)
1. Efficacy, safety and pharmacokinetics of biosimilars of anti-tumor necrosis factor-α agents in rheumatic diseases; A systematic review and meta-analysis. Komaki Y; Yamada A; Komaki F; Kudaravalli P; Micic D; Ido A; Sakuraba A J Autoimmun; 2017 May; 79():4-16. PubMed ID: 28209290 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review. Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131 [TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy and safety of tumor necrosis factor inhibitors and their biosimilars in patients with rheumatoid arthritis having an insufficient response to methotrexate : A network meta-analysis. Ho Lee Y; Gyu Song G Z Rheumatol; 2023 Apr; 82(3):248-255. PubMed ID: 34223982 [TBL] [Abstract][Full Text] [Related]
4. A scientific update on biosimilar infliximab (CT-P13) in rheumatic diseases. Taylor P Expert Rev Clin Immunol; 2015; 11 Suppl 1():S1-4. PubMed ID: 26395831 [TBL] [Abstract][Full Text] [Related]
5. Therapeutic Equivalence of Biosimilar and Reference Biologic Drugs in Rheumatoid Arthritis: A Systematic Review and Meta-analysis. Ascef BO; Almeida MO; Medeiros-Ribeiro AC; Oliveira de Andrade DC; Oliveira Junior HA; de Soárez PC JAMA Netw Open; 2023 May; 6(5):e2315872. PubMed ID: 37234004 [TBL] [Abstract][Full Text] [Related]
6. Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-α agent (infliximab), in inflammatory bowel diseases. Komaki Y; Yamada A; Komaki F; Micic D; Ido A; Sakuraba A Aliment Pharmacol Ther; 2017 Apr; 45(8):1043-1057. PubMed ID: 28239873 [TBL] [Abstract][Full Text] [Related]
7. Equivalence and switching between biosimilars and reference molecules in rheumatoid arthritis: protocol for a systematic review and meta-analysis. Ascef BO; Almeida MO; de Medeiros Ribeiro AC; Andrade DCO; de Oliveira Júnior HA; Pereira TV; de Soárez PC Syst Rev; 2021 Jul; 10(1):205. PubMed ID: 34274019 [TBL] [Abstract][Full Text] [Related]
8. Era of biosimilars in rheumatology: reshaping the healthcare environment. Smolen JS; Goncalves J; Quinn M; Benedetti F; Lee JY RMD Open; 2019; 5(1):e000900. PubMed ID: 31245050 [TBL] [Abstract][Full Text] [Related]
9. [Anti-TNF biosimilars in chronic inflammatory bowel disease. What can rheumatologists learn from it?]. Schreiber S Z Rheumatol; 2015 Oct; 74(8):689-94. PubMed ID: 26450434 [TBL] [Abstract][Full Text] [Related]
10. Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. Saad AA; Symmons DP; Noyce PR; Ashcroft DM J Rheumatol; 2008 May; 35(5):883-90. PubMed ID: 18381787 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of antitumor necrosis factor(α) agents on patients with ankylosing spondylitis. Ren L; Li J; Luo R; Tang R; Zhu S; Wan L Am J Med Sci; 2013 Dec; 346(6):455-61. PubMed ID: 23715113 [TBL] [Abstract][Full Text] [Related]
12. [Autoimmune aspects of treatment with TNF-alpha inhibitors]. Kolarz B; Targońska-Stepniak B; Darmochwał-Kolarz D; Majdan M Postepy Hig Med Dosw (Online); 2007 Aug; 61():478-84. PubMed ID: 17786135 [TBL] [Abstract][Full Text] [Related]
14. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. Bongartz T; Sutton AJ; Sweeting MJ; Buchan I; Matteson EL; Montori V JAMA; 2006 May; 295(19):2275-85. PubMed ID: 16705109 [TBL] [Abstract][Full Text] [Related]
15. Comparative Efficacy and Safety of Biosimilar Rituximab and Originator Rituximab in Rheumatoid Arthritis and Non-Hodgkin's Lymphoma: A Systematic Review and Meta-analysis. Lee S; Lee H; Kim E BioDrugs; 2019 Oct; 33(5):469-483. PubMed ID: 31446557 [TBL] [Abstract][Full Text] [Related]
16. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease. Cepeda EJ; Williams FM; Ishimori ML; Weisman MH; Reveille JD Ann Rheum Dis; 2008 May; 67(5):710-2. PubMed ID: 18079191 [TBL] [Abstract][Full Text] [Related]
17. Outcome of pregnancy and neonatal complications with anti-tumor necrosis factor-α use in females with immune mediated diseases; a systematic review and meta-analysis. Komaki F; Komaki Y; Micic D; Ido A; Sakuraba A J Autoimmun; 2017 Jan; 76():38-52. PubMed ID: 27913060 [TBL] [Abstract][Full Text] [Related]
18. [Systematic review: safety and efficacy of anti-TNF in elderly patients]. Busquets N; Carmona L; Surís X Reumatol Clin; 2011; 7(2):104-12. PubMed ID: 21794793 [TBL] [Abstract][Full Text] [Related]
19. The Comparative Safety of TNF Inhibitors in Ankylosing Spondylitis-a Meta-Analysis Update of 14 Randomized Controlled Trials. Hou LQ; Jiang GX; Chen YF; Yang XM; Meng L; Xue M; Liu XG; Chen XC; Li X Clin Rev Allergy Immunol; 2018 Apr; 54(2):234-243. PubMed ID: 28717941 [TBL] [Abstract][Full Text] [Related]
20. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]